IFNAR1 Immune Modulator Regulating Tissue Factor Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective and specific agents for inflammatory diseases, autoimmune diseases, and rare congenital defects related to the interferon-alpha receptor (IFNAR1) and its associated inflammatory response, as well as for modulating the anti-tumor activity of the immune system.
Innovation Solution
The discovery of the interaction between tissue factor (TF) and IFNAR1, which antagonizes IFNAR1 signaling, providing a novel approach to modulate IFNAR1 signaling for therapeutic purposes, including the use of pharmaceuticals that regulate this interaction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If IFNAR1 is activated to treat inflammatory diseases, then anti-inflammatory effect is improved, but pro-tumor activity increases
Solution Approach 1:
The patent introduces tissue factor (TF) as an intermediary molecule that binds to IFNAR1 and modulates its signaling. TF acts as a mediator that can suppress IFNAR1-mediated pro-inflammatory responses while preserving anti-tumor activities, thereby resolving the contradiction between treating inflammation and maintaining anti-tumor effect
Solution Approach 2:
The patent changes the signaling parameters of IFNAR1 by introducing TF as a modulating factor. TF alters the downstream signaling pathways (JAK/STAT, MAPK, PI3K, Akt) to shift the balance from pro-inflammatory to anti-inflammatory effects, enabling treatment of inflammatory diseases without compromising anti-tumor activity
2Object-generated harmful factors
If IFNAR1 signaling is inhibited to treat tumor diseases, then anti-tumor activity is improved, but inflammatory response increases
Solution Approach 1:
TF serves as a selective modulator that can enhance IFNAR1 signaling in a context-dependent manner. By binding to IFNAR1, TF amplifies anti-tumor immune responses while simultaneously suppressing harmful inflammatory effects, enabling dual-purpose therapy
Solution Approach 2:
The patent demonstrates that TF-IFNAR1 interaction has multi-functional effects: it can promote anti-tumor immunity, suppress sterile inflammation, and maintain immune homeostasis. This universal modulator approach allows a single mechanism to address multiple disease states with opposing requirements
3Object-affected harmful factors
If TF binds to IFNAR1 to suppress inflammation, then anti-inflammatory effect is improved, but anti-tumor response decreases
Solution Approach 1:
The patent reveals that the TF-IFNAR1 interaction is dynamic and context-dependent. The binding affinity and signaling outcomes vary based on cellular context, stimulus type, and temporal dynamics, allowing the same interaction to produce anti-inflammatory effects in some contexts and pro-tumor effects in others
Data Source
Figure 1A~1D
Figure 1E~1G
Figure 1H~1J
AI summary
The invention refers to an interferon-a receptor (IFNAR1) immune modulator for use as a medicament for regulating the interaction of tissue factor (TF) and interferon-a receptor (IFNAR1) in a subject and especially to an IFNAR1 immune modulator for use as a medicament according for treating a tumor disease in a subject by regulating the interaction of TF and IFNAR1 or for treating chronic inflammatory disease, autoimmune diseases and/or interferonopathy in a subject by regulating the interaction of TF and IFNAR1.